Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study

References

• Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 2009;361:1045–1057
   PubMed Web of Science ®Google Scholar
• Van Giezen JJ, Sidaway J, Glaves P, Kirk I, Bjorkman JA. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Therapeut 2011;17:164–172
   PubMed Web of Science ®Google Scholar
• Storey RF, Angiolillo D, Patil S, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon C, Becker R, Wallentin L. Inhibitory effects of ticagrelor compared to clopidogrel on platelet function in patients with acute coronary syndromes: The PLATO PLATELET Substudy. J Am Coll Cardiol 2010;56:1456–1462
   PubMed Web of Science ®Google Scholar
• Nurden AT. Platelets, inflammation and tissue regeneration. Thrombosis Haemostasis 2011;105(Suppl 1):S13–S33
   PubMed Web of Science ®Google Scholar
• Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharmaceut Design 2006;12:1255–1259
   PubMed Web of Science ®Google Scholar
• Evans DJW, Jackman LE, Chamberlain J, Crosdale DJ, Judge HM, Jetha K, Norman KE, Francis SE, Storey RF. The platelet P2Y12 receptor influences the vessel wall response to arterial injury and thrombosis. Circulation 2009;119:116–122
   PubMed Web of Science ®Google Scholar
• Jacobson KA, Gao Z-G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5:247–264
   PubMed Web of Science ®Google Scholar
• Guasti L, Dentali F, Castiglioni L, Maroni L, Marino F, Squizzato A, Ageno W, Gianni M, Gaudio G, Grandi AM, et al. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A systematic review on more than 34,000 subjects. Thrombosis Haemostasis 2011;106:591–599
   PubMed Web of Science ®Google Scholar
• Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2005;2:29–36
   PubMedGoogle Scholar
• James SK, Lindahl B, Timmer JR, Ottervanger JP, Siegbahn A, Stridsberg M, Armstrong P, Califf R, Wallentin L, Simoons ML. Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non–ST-elevation acute coronary syndromes (A GUSTO IV Substudy). Am J Cardiol 2006;97:167–172
   PubMed Web of Science ®Google Scholar
• Zamani P, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P, Ganz P, Kinlay S, for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc 2013;2:E-pub
   Google Scholar
• Storey RF, James S, Åsenblad N, Siegbahn A, Emanuelsson H, Katus H, Cannon C, Husted S, Steg P, Wallentin L. Consistent benefit of ticagrelor compared to clopidogrel in acute coronary syndrome patients regardless of baseline inflammatory markers. J Am Coll Cardiol 2012;59:E505 (abstract)
   Web of Science ®Google Scholar
• James S, Åkerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene S, Steg PG, Storey RF, Harrington R, et al. Comparison of Ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157:599–605
   PubMed Web of Science ®Google Scholar
• Storey RF, Bliden K, Patil SB, Karunakaran A, Ecob R, Butler K, Teng R, Wei C, Tantry US, Gurbel P. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 2010;56:185–193
   PubMed Web of Science ®Google Scholar
• Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Cooper A, et al. Characterisation of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011;32:2945–2953
   PubMed Web of Science ®Google Scholar
• Cox D, Kerrigan SW, Watson SP. Platelets and the innate immune system: Mechanisms of bacterial-induced platelet activation. J Thrombosis Haemostasis 2011;9:1097–1107
   PubMed Web of Science ®Google Scholar
• Russwurm S, Vickers J, Meier-Hellmann A, Spangenberg P, Bredle D, Reinhart K, Lösche W. Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock 2002;17:263–268
   PubMed Web of Science ®Google Scholar
• Winning J, Reichel J, Eisenhut Y, Hamacher J, Kohl M, Deigner HP, Claus RA, Bauer M, Lösche W. Anti-platelet drugs and outcome in severe infection: Clinical impact and underlying mechanisms. Platelets 2009;20:50–57
   PubMed Web of Science ®Google Scholar
• Otto GP, Sossdorf M, Boettel J, Kabisch B, Breuel H, Winning J, Lösche W. Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock. Platelets 2013;24:480–485
   PubMed Web of Science ®Google Scholar
• Seidel M, Winning J, Claus RA, Bauer M, LÖSche W. Beneficial effect of clopidogrel in a mouse model of polymicrobial sepsis. J Thrombosis Haemostasis 2009;7:1030–1032
   PubMed Web of Science ®Google Scholar
• Winning J, Neumann J, Kohl M, Claus RA, Reinhart K, Bauer M, Lösche W. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit*. Critical Care Med 2010;38:32–37
   PubMed Web of Science ®Google Scholar
• Rahman M, Gustafsson D, Wang Y, Thorlacius H, Braun OO. Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis. Platelets 2013;E-pub July 15
   Google Scholar
• The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001;345:494–502
   PubMed Web of Science ®Google Scholar
• Wiviott S, Braunwald E, McCabe C, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 2007;357:2001–2015
   PubMed Web of Science ®Google Scholar
• Roe MT, Armstrong PW, Fox KAA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. New Engl J Med 2012;367:1297–1309
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS, COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. The Lancet 2005;366:1607–1621
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Nakada MT, Topol EJ. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163–167
   PubMed Web of Science ®Google Scholar
• Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJJ, Jonasson J, Nylander S, Gan L-M. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol 2013;61:723–727
   PubMed Web of Science ®Google Scholar
• Scirica B, Cannon C, Emanuelsson H, Michelson E, Harrington R, Husted S, James S, Katus H, Pais P, Raev D, et al. The incidence of arrhythmias and clinical arrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO trial. J Am Coll Cardiol 2011;57:1908–1916
   PubMed Web of Science ®Google Scholar
• Barletta KE, Ley K, Mehrad B. Regulation of neutrophil function by adenosine. Arteriosclerosis, Thrombosis, Vasc Biol 2012;32:856–864
   PubMed Web of Science ®Google Scholar
• Balamuthusamy S, Arora R. Hematologic adverse effects of clopidogrel. Am J Therapeut 2007;14:106–112
   PubMedGoogle Scholar
• Blasco-Colmenares E, Perl TM, Guallar E, Baumgartner W, Conte J, Alejo D, Pastor-Barriuso R, Sharrett A, Faraday N. Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery. Arch Intern Med 2009;169:788–795
   PubMedGoogle Scholar
• Varenhorst C, Alstrom U, Scirica BM, Hogue CW, Asenblad N, Storey RF, Steg PG, Horrow J, Becker RC, James S, et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 2012;60:1623–1630
   PubMed Web of Science ®Google Scholar
• Gross AK, Dunn SP, Feola DJ, Martin CA, Charnigo R, Li Z, Abdel-Latif A, Smyth SS. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis 2013;35:147–154
   PubMed Web of Science ®Google Scholar